Pay in 4 interest-free payments of $6.59 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
00:27:46 Jennifer Clements Again, I think theres many different factors that go into it
The phase 2 trial published in The New England Journal of Medicine in 2023 enrolled adults with obesity without type 2 diabetes and demonstrated dose-dependent weight loss of up to 24.2% of body weight at the highest dose over 48 weeks results that attracted considerable scientific and media attention
Some positive results thus far have encouraged additional research into the topic
Storage requirements Lyophilized (powder) 20C up to 24 months Reconstituted 28C up to 21 days Literature Peer-reviewed research for laboratory background Annals of the New York Academy of Sciences 1997 PMID 9415996 Safer D et al
Survodutide is another dual GLP-1/glucagon agonist in development
:max_bytes(150000):strip_icc()/VWH-GettyImages-2126120259-c2442d334436484baa255439265b7fb1.jpg)
US$ 28.37
US$ 24.37
US$ 29.54
US$ 23.21
